This website is dedicated to providing public information regarding DePuy Hip recall and other related information to the recall. None of the information on this site is intended to be formal legal or medical advice, nor should any information on this site be construed as advice that should be used in lieu of information from your attorney or physician.
Saturday, September 1, 2012
Hip Resrufacing results of 10 year survival statistics
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK.
Recent events have highlighted the importance of implant design for survival and wear-related complications followingmetal-on-metalhipresurfacing arthroplasty. The mid-term survival of the most widely used implant, the BirminghamHipResurfacing (BHR), has been described by its designers. The aim of this study was to report the ten-year survival and patient-reported functional outcome of the BHR from an independent centre. In this cohort of 554 patients (646 BHRs) with a mean age of 51.9 years (16.5 to 81.5) followed for a mean of eight years (1 to 12), the survival and patient-reported functional outcome depended on gender and the size of the implant. In female hips (n = 267) the ten-year survival was 74% (95% confidence interval (CI) 83 to 91), the ten-year revision rate for pseudotumour was 7%, the mean Oxfordhipscore (OHS) was 43 (sd 8) and the mean UCLA activity score was 6.4 (sd 2). In male hips (n = 379) the ten-year survival was 95% (95% CI 92.0 to 97.4), the ten-year revision rate for pseudotumour was 1.7%, the mean OHS was 45 (sd 6) and the mean UCLA score was 7.6 (sd 2). In the most demanding subgroup, comprising male patients aged < 50 years treated for primary osteoarthritis, the survival was 99% (95% CI 97 to 100). This study supports the ongoing use of resurfacing in young active men, who are a subgroup of patients who tend to have problems with conventional THR. In contrast, the results in women have been poor and we do not recommendmetal-on-metalresurfacing in women. Continuous follow-up is recommended because of the increasing incidence of pseudotumour with the passage of time.